That’s what this drug company is trying to do. It probably would be better to spend their resources trying to find something new, rather than repackaging old drugs (case in point: BiDil).
Do we really need brand name amoxicillin?
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
More in Uncategorized
Past Week
-
How smartphones are stealing your focus—and what you can do about it
-
Learning to trust your body again: Healing the hidden wounds of medical training
-
Are quotas a solution to physician shortages?
-
Why patients and doctors are ditching insurance for personalized care
-
Internal Medicine 2025: inspiration at the annual meeting
-
When grief hits all at once: a morning of heartbreak and love
-
Past 6 Months
-
How trade wars could destroy the U.S. health care system
-
How hospitals are quietly taking control of physicians
-
What happened to real care in health care?
-
The silent crisis hurting pain patients and their doctors
-
Doctors don’t need yoga, they need time to smoke
-
Academic medical centers under threat: the impact of funding cuts
-
Recent Posts
-
The origin of medical licensing exams
-
Focusing on medicine’s core, not administrative chores [PODCAST]
-
When America sneezes, the world catches a cold: Trump’s freeze on HIV/AIDS funding
-
Burnout isn’t ironclad—and neither are we
-
Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies
-
Clinicians must be scrupulously honest in and out of work
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
